FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168579675> ?p ?o ?g. }

• W3168579675 endingPage "e13031" @default.
• W3168579675 startingPage "e13031" @default.
• W3168579675 abstract "e13031 Background: The use of CDKIs have transformed the management of ER+HER2- mBC. As the real-world data matures, this project describes patterns in response to systemic therapy that may inform treatment planning and prognostication. Methods: We analysed the ER+HER2- mBC dataset at Nottingham University Hospitals NHS Trust (NUH) generated by reviewing clinical notes, radiology and e-prescribing records to collect clinical data on patients treated with CDKIs between 01/10/2016 - 01/10/2020. Results: 272 patients with a median age of 65 years (30-90 years) were treated with CDKIs (palbociclib 54.0% (n=147); ribociclib 19.5% (n=53); abemaciclib 26.5% (n=72)) in combination with endocrine therapies (letrozole, anastrozole, exemestane and, fulvestrant). Median overall survival was 49.5 months. Treatment with first-line CDKIs (69.8%; n=190) resulted in superior PFS when compared to CDKIs in a ≥ second-line setting (30.2%; n=82) i.e., mPFS 21.3 vs 12.2 months (HR 0.67; 95% CI, 0.47-0.96; P=0.02). Univariate analysis shown in the table below indicates the benefit to PFS from presentations with de novo mBC and the absence of visceral metastases. In patients treated curatively for early breast cancer (EBC), better outcomes were demonstrated in patients presenting with mBC, >12 months versus ≤12 months of completion of adjuvant endocrine therapy i.e., mPFS 28.4 vs 12.1 months (HR 0.50; 95% CI, 0.30-0.84; P=0.004) when treated with first-line CDKIs. A multivariate analysis identified benefit to PFS from first-line therapy with CDKIs (HR 0.70; 95% CI, 0.49-1.01; P=0.05) and presentation with de novo mBC (HR 0.56; 95% CI, 0.37-0.85; P=0.006). The presence of visceral metastases was associated with poorer outcomes (HR 1.52; 95% CI, 1.08-2.15; P=0.01). Conclusions: This analysis confirms the PFS benefit from CDKIs demonstrated in clinical trials is mirrored in the real-world setting. The analysis was not powered to delineate survival benefit between the individual CDKIs. Presentations with mBC following a prior history of EBC, within ≤12 months of completion of adjuvant endocrine therapy, and with visceral metastases may help predict poorer clinical outcomes and may need to be considered when prognosticating and in treatment planning. This analysis is hypotheses-generating and we will confirm our findings in a prospective manner as the dataset is expanded.[Table: see text]" @default.
• W3168579675 created "2021-06-22" @default.
• W3168579675 creator A5011969138 @default.
• W3168579675 creator A5012126052 @default.
• W3168579675 creator A5026719707 @default.
• W3168579675 creator A5029177733 @default.
• W3168579675 creator A5032372555 @default.
• W3168579675 creator A5047818181 @default.
• W3168579675 creator A5056848636 @default.
• W3168579675 creator A5068336795 @default.
• W3168579675 creator A5078412433 @default.
• W3168579675 date "2021-05-20" @default.
• W3168579675 modified "2023-09-26" @default.
• W3168579675 title "Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC)." @default.
• W3168579675 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e13031" @default.
• W3168579675 hasPublicationYear "2021" @default.
• W3168579675 type Work @default.
• W3168579675 sameAs 3168579675 @default.
• W3168579675 citedByCount "1" @default.
• W3168579675 countsByYear W31685796752022 @default.
• W3168579675 crossrefType "journal-article" @default.
• W3168579675 hasAuthorship W3168579675A5011969138 @default.
• W3168579675 hasAuthorship W3168579675A5012126052 @default.
• W3168579675 hasAuthorship W3168579675A5026719707 @default.
• W3168579675 hasAuthorship W3168579675A5029177733 @default.
• W3168579675 hasAuthorship W3168579675A5032372555 @default.
• W3168579675 hasAuthorship W3168579675A5047818181 @default.
• W3168579675 hasAuthorship W3168579675A5056848636 @default.
• W3168579675 hasAuthorship W3168579675A5068336795 @default.
• W3168579675 hasAuthorship W3168579675A5078412433 @default.
• W3168579675 hasConcept C121608353 @default.
• W3168579675 hasConcept C126322002 @default.
• W3168579675 hasConcept C143998085 @default.
• W3168579675 hasConcept C144301174 @default.
• W3168579675 hasConcept C2775860665 @default.
• W3168579675 hasConcept C2775930923 @default.
• W3168579675 hasConcept C2777176818 @default.
• W3168579675 hasConcept C2778812593 @default.
• W3168579675 hasConcept C2779744173 @default.
• W3168579675 hasConcept C2780482068 @default.
• W3168579675 hasConcept C38180746 @default.
• W3168579675 hasConcept C530470458 @default.
• W3168579675 hasConcept C71924100 @default.
• W3168579675 hasConceptScore W3168579675C121608353 @default.
• W3168579675 hasConceptScore W3168579675C126322002 @default.
• W3168579675 hasConceptScore W3168579675C143998085 @default.
• W3168579675 hasConceptScore W3168579675C144301174 @default.
• W3168579675 hasConceptScore W3168579675C2775860665 @default.
• W3168579675 hasConceptScore W3168579675C2775930923 @default.
• W3168579675 hasConceptScore W3168579675C2777176818 @default.
• W3168579675 hasConceptScore W3168579675C2778812593 @default.
• W3168579675 hasConceptScore W3168579675C2779744173 @default.
• W3168579675 hasConceptScore W3168579675C2780482068 @default.
• W3168579675 hasConceptScore W3168579675C38180746 @default.
• W3168579675 hasConceptScore W3168579675C530470458 @default.
• W3168579675 hasConceptScore W3168579675C71924100 @default.
• W3168579675 hasIssue "15_suppl" @default.
• W3168579675 hasLocation W31685796751 @default.
• W3168579675 hasOpenAccess W3168579675 @default.
• W3168579675 hasPrimaryLocation W31685796751 @default.
• W3168579675 hasRelatedWork W2100085165 @default.
• W3168579675 hasRelatedWork W2444222831 @default.
• W3168579675 hasRelatedWork W2610563129 @default.
• W3168579675 hasRelatedWork W2747078758 @default.
• W3168579675 hasRelatedWork W2753431361 @default.
• W3168579675 hasRelatedWork W2762467781 @default.
• W3168579675 hasRelatedWork W2767256081 @default.
• W3168579675 hasRelatedWork W3006288965 @default.
• W3168579675 hasRelatedWork W3203690439 @default.
• W3168579675 hasRelatedWork W4226356606 @default.
• W3168579675 hasVolume "39" @default.
• W3168579675 isParatext "false" @default.
• W3168579675 isRetracted "false" @default.
• W3168579675 magId "3168579675" @default.
• W3168579675 workType "article" @default.